UNIVEST FINANCIAL Corp Acquires 12,924 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

UNIVEST FINANCIAL Corp acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, Holdings Channel reports. The fund acquired 12,924 shares of the biopharmaceutical company’s stock, valued at approximately $3,189,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SCS Capital Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $34,784,000. WINTON GROUP Ltd purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at about $2,372,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $50,773,000. Silvant Capital Management LLC acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $5,456,000. Finally, Wealthfront Advisers LLC acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $2,876,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $159.85 on Thursday. The company has a market cap of $21.41 billion, a P/E ratio of 8.30 and a beta of 0.42. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $149.18 and a fifty-two week high of $479.79. The company has a quick ratio of 2.43, a current ratio of 2.48 and a debt-to-equity ratio of 0.18. The firm’s 50 day moving average price is $223.45 and its 200 day moving average price is $277.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the previous year, the firm posted $2.90 earnings per share. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Raymond James Financial lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and decreased their target price for the stock from $420.00 to $315.00 in a research note on Friday, October 30th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 30th. Sanford C. Bernstein downgraded Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $376.00 to $199.00 in a research report on Friday, October 30th. Stifel Nicolaus lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 price objective on the stock. in a research note on Thursday, October 29th. Finally, HC Wainwright restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $305.86.

Insider Activity

In related news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.